Compare
Corcept Therapeutics Inc vs Emergent BioSolutions Inc. vs Pacira BioSciences, Inc. vs Kiniksa Pharmaceuticals International, plc
| Latest fiscal year | Corcept Therapeutics Inc CORT | Emergent BioSolutions Inc. EBS | Pacira BioSciences, Inc. PCRX | Kiniksa Pharmaceuticals International, plc KNSA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $761.41M | $742.90M | $726.41M | $677.56M |
| Revenue growth (YoY) | +12.8% | -28.8% | +3.6% | +60.1% |
| Gross margin | n/a | 56.1% (computed) | 79.4% (computed) | 88.5% (computed) |
| Operating margin | 5.9% | 13.5% | 2.6% | 11.4% |
| Net margin | 13.1% | 7.1% | 1.0% | 8.7% |
| Net income | $99.65M | $52.60M | $7.03M | $59.01M |
| EPS (Diluted) | $0.82 | $0.93 | $0.16 | $0.75 |
| Operating cash flow | $142.00M | $170.60M | $151.99M | $137.99M |
| Free cash flow | $141.78M | $156.80M | $136.66M | $136.42M |
| Cash & equivalents | $120.50M | $205.40M | $158.54M | $165.60M |
| Total assets | $836.65M | $1.32B | $1.26B | $763.63M |
| Total liabilities | $188.85M | $796.00M | $571.81M | $196.03M |
| Shareholders' equity | $647.80M | $522.60M | $693.11M | $567.61M |
| Return on year-end equity | 15.4% | 10.1% | 1.0% | 10.4% |
| Shares outstanding | 105.97M | 52.10M | 41.12M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Corcept Therapeutics Inc | Emergent BioSolutions Inc. | Pacira BioSciences, Inc. | Kiniksa Pharmaceuticals International, plc |
|---|---|---|---|---|
| Latest | $761.41M Ended 2025-12-31 | $742.90M Ended 2025-12-31 | $726.41M Ended 2025-12-31 | $677.56M Ended 2025-12-31 |
| 1 year earlier | $675.04M Ended 2024-12-31 | $1.04B Ended 2024-12-31 | $700.97M Ended 2024-12-31 | $423.24M Ended 2024-12-31 |
| 2 years earlier | $482.38M Ended 2023-12-31 | $1.05B Ended 2023-12-31 | $674.98M Ended 2023-12-31 | $270.26M Ended 2023-12-31 |
| 3 years earlier | $401.86M Ended 2022-12-31 | $1.12B Ended 2022-12-31 | $666.82M Ended 2022-12-31 | $220.18M Ended 2022-12-31 |
| 4 years earlier | $365.98M Ended 2021-12-31 | $1.77B Ended 2021-12-31 | $541.53M Ended 2021-12-31 | $38.54M Ended 2021-12-31 |